Koshinski Asset Management
BCTX

Koshinski Asset Management’s Briacell Therapeutics BCTX Stock Holding History

Koshinski Asset Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$5.07K – 696
2022
Q1 		$5.07K Hold
3
– – ﹤0.01% 1787
2021
Q4 		$4.14K Buy
+3
New +$3.93K ﹤0.01% 1841

Other funds holding BCTX

KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Koshinski Asset Management's BCTX Position: Q2 2022 in Review

Koshinski Asset Management sold out of Briacell Therapeutics (BCTX) in Q2 2022, closing a stake of 3 shares — an estimated $5.07K sold.

Koshinski Asset Management first reported a position in BCTX in Q4 2021 and held it in 2 quarters. The position peaked at $5.07K in Q1 2022. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2022.

  • Koshinski Asset Management reported no remaining Briacell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 3 Briacell Therapeutics shares in Q2 2022, an estimated $5.07K.
  • Koshinski Asset Management first reported a position in Briacell Therapeutics in Q4 2021 and held it in 2 quarters.
  • Koshinski Asset Management's Briacell Therapeutics position peaked at $5.07K in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.